https://orcid.org/0000-0002-4336-1071
The patient is a 66-year-old woman with chemorefractory diffuse large B-cell lymphoma who received axicabtagene ciloleucel anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. On day +1 after CAR infusion she developed a fever consistent with grade 1 cytokine release syndrome (CRS). She received 2 doses of tocilizumab, 8 mg/kg, on days +6 and +7 for persistent CRS. On day +8 she developed word finding difficulty and started IV dexamethasone, 10 mg every 6 hours. On day +9 she progressed with grade 2 ICANS (immune effector cell–associated neurotoxicity syndrome). Brain magnetic resonance imaging was unrevealing. Lumbar puncture with cerebrospinal fluid (CSF) analysis revealed an elevated white blood cell count (39/μL) without evidence of lymphoma. Immunophenotypic analysis demonstrated 55% T cells and no B cells. Wright-stained CSF cytospin revealed many hemophagocytic histiocytes (panel A, original magnification ×100; panel B, ×1000) consistent with a dysregulated immune response after CAR T-cell therapy. She received intrathecal hydrocortisone, 100 mg, with improvement. On day +13 she had recurrent grade 3 ICANS and received intrathecal hydrocortisone+methotrexate+cytarabine with full neurological recovery by day +14. Peak levels of ferritin, C-reactive protein, and lactate dehydrogenase in the first 28 days were 387 ng/mL, 14.93 mg/dL, and 287 U/L, respectively. She achieved remission and remains relapse free at 4 months posttreatment.
ICANS remains a clinical challenge of CAR T-cell therapy. The image demonstrates the role of macrophage activation in the development of ICANS and the ability of intrathecal treatment to reverse toxicity.
The patient is a 66-year-old woman with chemorefractory diffuse large B-cell lymphoma who received axicabtagene ciloleucel anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. On day +1 after CAR infusion she developed a fever consistent with grade 1 cytokine release syndrome (CRS). She received 2 doses of tocilizumab, 8 mg/kg, on days +6 and +7 for persistent CRS. On day +8 she developed word finding difficulty and started IV dexamethasone, 10 mg every 6 hours. On day +9 she progressed with grade 2 ICANS (immune effector cell–associated neurotoxicity syndrome). Brain magnetic resonance imaging was unrevealing. Lumbar puncture with cerebrospinal fluid (CSF) analysis revealed an elevated white blood cell count (39/μL) without evidence of lymphoma. Immunophenotypic analysis demonstrated 55% T cells and no B cells. Wright-stained CSF cytospin revealed many hemophagocytic histiocytes (panel A, original magnification ×100; panel B, ×1000) consistent with a dysregulated immune response after CAR T-cell therapy. She received intrathecal hydrocortisone, 100 mg, with improvement. On day +13 she had recurrent grade 3 ICANS and received intrathecal hydrocortisone+methotrexate+cytarabine with full neurological recovery by day +14. Peak levels of ferritin, C-reactive protein, and lactate dehydrogenase in the first 28 days were 387 ng/mL, 14.93 mg/dL, and 287 U/L, respectively. She achieved remission and remains relapse free at 4 months posttreatment.
ICANS remains a clinical challenge of CAR T-cell therapy. The image demonstrates the role of macrophage activation in the development of ICANS and the ability of intrathecal treatment to reverse toxicity.
For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.
